Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-722 SAD and MAD in Healthy Adults
NCT06673238Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised trial of ABBV-722 (12 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events Reported During Safety Evaluations, Maximum Plasma Concentration of ABBV-722 and 9 more. Started Oct 2024; status: completed.
02
Drugs
ABBV-722
Beyond the preview
Go deeper on NCT06673238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673238.